Studies suggest that inflammation is involved in the neurodegenerative cascade of dementias. Immunological mechanisms may be part of the pathophysiological process in frontotemporal dementia (FTD), but up till now only vague evidence of such mechanisms has been presented. The B7-CD28/CTLA-4 pathway is an important immunological signaling pathway involved in modulation of T cell activation. The aim of this study was to compare the expression of molecules associated with co-stimulatory signaling in peripheral blood mononuclear cells (PBMC) of FTD to Alzheimer disease (AD) and control groups. Our results confirm the previous demonstrated increased expression of CD80 in CD14+ Alzheimer patients T cells but show, for the first time, a reduction in the expression of CTLA-4 in CD4+ FTD cells. As CTLA-4 is the most potent negative regulators of T-cell activation we speculated that peripheral T lymphocytes in FTD are more activated and this could be involved in the neurodegeneration observed in this dementia.
Frontotemporal dementia (FTD) is an umbrella term that groups several different neurodegenerative diseases characterized by predominant destruction of the frontal and temporal lobe. It is a clinical syndrome marked by progressive changes in personality and interpersonal conduct (behavioural-variant frontotemporal dementia -bvFTD), or language (progressive nonfluent aphasia, PNAF, or semantic dementia, SD). Patients with bvFTD are disinhibited, socially inappropriate, and show a lack of insight and concern (McKhann et al., 2001 ). Other patients predominantly present with apathy, inertia, and loss of volition (Snowden et al., 2001 ). Expressive language is the hallmark of PNAF patients whilst deterioration of verbal and non-verbal conceptual knowledge is characteristic of SD. In clinical practice FTD is commonly misdiagnosed as Alzheimer disease (Hodges and Patterson, 2007) .
The ability to discriminate between self and non self is one the most fundamentally important aspects of the immune system. This ability is achieved by complex regulation mechanisms involving immune cells and molecules including cytokines and chemokines. When this complex regulation process is altered the immune system's destructive effects become evident. Cytokines and their receptors are expressed physiologically in central nervous system (CNS) cells and are important for development and function of the brain (Schmitz and Chew, 2008) . The detrimental effect of immune system on CNS is seen in many conditions such as multiple sclerosis. There is considerable evidence to suggest that an inflammatory response may be involved in the neurodegenerative cascade in Alzheimer disease (AD) and other dementias as well (Eikelenboom et al., 2010; McGeer and McGeer, 2010) .
One mechanism designed to maintain the fidelity of the immune response is the two-signal concept of lymphocyte activation: an antigenspecific signal via the T cell receptor (Signal 1) and a co-stimulatory signal (Signal 2) that is provided by soluble factors or cell-surface molecules on the antigen presenting cell (APC) (Bretscher, 1999) .
Signal 1 is provided by interaction of the antigen with the majorhistocompatibility-complex (MHC) and T-cell-receptor (TCR). In the absence of signal 2,lymphocytes are usually rendered anergic, but when this signal is very strong lymphocyte activation can occur. Signal 2 is delivered to T cells by co-stimulatory cell surface molecules expressed on antigen-presenting cells (APC) (Bretscher, 1999 Contents lists available at ScienceDirect
Progress in Neuro-Psychopharmacology & Biological Psychiatry j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / p n p is crucial for the immunological system. Negative second signal induces T cell tolerance, whereas a positive signal promotes T cell activation (Sharpe and Freeman, 2002) . The main co-stimulatory signal is the B7-1/B7-2-CD28/CTLA-4 pathway. B7-1(CD80) and B7-2 (CD86) located on the surface of APC have specificity for the stimulatory receptor (CD28) or the inhibitory receptor CTLA-4 (CD152). Signalling through CD28 promotes cytokine production (IL-2 and TNF-α), increases CD40L and enhances T cell survival by activation of NF-κβ and upregulation of Bcl-X L (Boise et al., 1995; Sperling et al., 1996; Thompson et al., 1989) . The opposing outcome is observed with CTLA-4 engagement which inhibits IL-2 synthesis and causes a T cell cycle arrest. CTLA-4 has a crucial role in regulating peripheral T cell tolerance (Greenwald et al., 2002; Oosterwegel et al., 1999) . To our knowledge, there are no studies evaluating the pathway B7-CD28/CTLA-4 pathway in AD or FTD. Therefore, the aim of this study is to evaluate the expression of molecules associated with costimulatory signalling in peripheral blood mononuclear cells (PBMC) of FTD patients compared to Alzheimer disease (AD) patients.
Subjects and methods
Patients were selected from the outpatient clinic of Jenny de Andrade Faria Geriatric Institute of Universidade de Minas Gerais (UFMG)-Brazil, which is the elderly reference centre in the state of Minas Gerais. The Ethics Committee of the federal university, UFMG, approved the study and all procedures were according to the local board of regulation. All patients were evaluated using the institute's full standard 1 evaluation protocol. They were also evaluated by at least two physicians. Neuropsychology and phonological specialists evaluated the patients when necessary. To be enrolled, study subjects fulfilled the standard clinical criteria for probable or possible AD (McKhann et al., 1984) , or FTD (Neary et al., 1998) . Severe demented patients (clinical dementia rate equals to 3 or with impairment in basic activity of daily life) were not allowed to be enrolled. Patients who performed the same protocol evaluation, including cognitive tests, without any significant finding or depression, were enrolled in the control group. Besides diagnosis criteria already mentioned, all patients fulfilled exclusion criteria, therefore they did not have the following conditions: inflammatory disease; acute conditions at the time of blood collection; any decompensated chronic disease (including diabetes mellitus, chronic pulmonary disease) or any other neuropsychiatric disorder. Blood was collected from patients and peripheral blood mononuclear cells (PBMC) were obtained using a Ficoll/Hypaque gradient. Flow cytometric analysis was performed as described by Torres et al., 2005 (Torres et al., 2005 . PBMC were cultured in RPMI (Roswell Park Memorial Institute-1640) supplemented with 10% foetal bovine serum, 200 μL de L-glutamine and 1% penicillin-streptomicin. This procedure was undertaken to increase costimulatory surface marker expression. Cells were then stained with antibody solutions. The antibodies used for staining of antigens expressed on the cell surface were anti-CD19-Cy, anti-CD4-FITC, anti-CD14-FITC, anti-CD80-PE, anti-CD28-PE and anti-CTLA-4-Cy5. Additionally, FITC, PE and Cy5-labeled immunoglobulin isotype control antibodies were included in all experiments. Next, the preparations were washed and fixed with 2% formaldehyde. The stained cells were acquired and analysed using a flow cytometer (Guava/GE). Leucocytes were analysed for their surface marker frequencies using the Cytosoft program. Statistical analyses were performed using the software GraphPad Prism, version 6.0c, for Mac, March 2013. The nonparametric Kruskal-Wallis one-way analysis test of variance following Dunn's Multiple Comparison test was used for comparing the distribution of the three unmatched groups (FTD, AD and control group). When comparison was made between the two groups (FTD and AD) a Mann Whitney test was used. The frequency of gender distribution was tested among the three groups using Chi-squared test. In all cases two-tail P-values less than 0.05 were taken to be significant. A normality test (Shapiro-Wilk normality test and D'Agostino-Pearson omnibus test) was also used to support the use of non-parametric test. All graphs were plotted using the traditional Tukey box-andwhisker. The top and bottom of the box are always the 25th and 75th percentiles plot and the line inside the box is the median. Results, along the text, are presented as median (25th-75th percentile). Any data beyond the whiskers (outliers) are shown as points (as shown in Fig. 2B ).
Results
A total of 46 patients were included in this study. They were divided into three groups: 27 AD, 10FTD and 9 control patients. The frontotemporal dementia group was composed of: 7 patients with behaviour variant frontotemporal dementia (bvFTD), 2 patients with progressive non-fluent aphasia (PNAF), and 1 patient with semantic dementia (SD). Only mild to moderate demented patients were enrolled in this study. FTD group was statistically different from both groups when age was analysed by Kruskal-Wallis oneway analysis of variance followed by Dunn's Multiple Comparison test (p b 0.0001). Mini Mental State Examination (MMSE) was different when AD and control group were analysed, but there was no statistical difference when AD and FTD were analysed.
The first step performed in order to study co-stimulatory receptorligand pair in T cell response measured the surface expression of B7-1 (CD80, which is the ligant for CD28) in CD14+ (monocytes) and in CD19+ (lymphocyte B) cells (Fig. 1) which is the ligand for CD28. Its expression is inducible in antigen-presenting cells or dendritic cells upon stimulation. As shown in Fig. 1 When comparison was performed in FTD and AD (using Mann Whitney test), a reduction in IL-1α (p = 0.025) and HLA-DR (p = 0.039) was detected.
Discussion
Neurodegenerative diseases are characterized by significant neuronal loss. Despite the progress made in the last decade in understanding the molecular mechanism that causes neuronal loss in FTD, it is still a field in its infancy. Immune molecules such as cytokines are involved in neuronal death causing dementia processes. The literature clearly shows that peripheral T cells are activated in AD (Liu et al., 2010; Schindowski et al., 2007; Town et al., 2005) .
When B7-1 (CD80) binds to its stimulatory receptor (CD28), cytokine production (IL-2 and TNF-α) is promoted (Sperling et al., 1996) . B7-2 (CD86) is also a ligand for CD28, which is inducible later in the immune response (Goronzy and Weyand, 2008) . The B7-1 ⁄ B7-2 ⁄ CD28 pathway has been shown to constitute the primary and strongest costimulatory signal delivered by APCs to amplify Tcell activation (Green et al., 1994) . Meta-analysis reports significantly higher concentrations of the proinflammatory cytokines IL-6, TNF-α, IL-1β, IL-12, and IL-18 in the peripheral blood of AD subjects compared with control subjects (Swardfager et al., 2010) .
A recent work from Xue et al. (2009) shows an increase in HLA-DR and CD80 molecules from Alzheimer patients' blood. The increase in CD80 expression in CD4 + observed in our study is in agreement with this work and it also supports the idea that T cells are involved in AD pathology. AD is the main differential diagnosis of FTD in clinical practice. When HLA-DR expression was compared in these two groups a reduction in its expression was observed in FTD. HLA-DR allows antigen presentation to T cells and is crucial for the initiation of the immune cascade (Unanue et al., 1984) . CD14 + cells seem to be less activated in FTD when compared to AD. This idea is supported by the reduction of IL-1α expression, as shown in Fig. 3B . The reduction of HLA-DR and IL-1α in FTD highlight the contrast between these two conditions regarding their immune profile. CD 28 is also expressed not only in CD4+ T cells (Fig. 2) but in CD8+ T cells as well. Normally during aging, loss of CD28 is expected to occur in T cells, mainly in CD8 + T cells, and this process may be accelerated in susceptible individuals. One mechanism to explain this is based on the capability of tumour necrosis factor (TNF) to down regulate CD28 molecules (Bryl et al., 2001) . Although the FTD group is slightly younger than the other groups, there is no difference in CD28 expression. As we analysed CD28 expression in CD4+ T cells, aging is not expected to interfere in this results. In addition to the effect on cytokine production previously mentioned, CD28 signalling also provides a potent synergistic signal for transcription factors such as nuclear factor-κβ(NF-κβ), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP1) (Goronzy and Weyand, 2008) . CTLA-4 has an inhibitory effect in this pathway and its signal mediates cell death (Kane et al., 2002; Rincón and Flavell, 1994) .
When CTLA-4 expression was analysed a striking reduction was observed in FTD patients compared to AD or control groups. This reduction in the inhibitory molecule may reduce its ability to oppose stimulatory effects promoted by CD80 or CD86. The mechanism responsible for the regulation of CD28 and CTLA-4 expression vary considerably. CD28 is constitutively expressed on CD4 + T cells, on the other hand, CTLA-4 expression is induced in response to TCR ligation and the majority is localized in several intracellular compartments. Minor differences in its expression can have potentially detrimental effects, such as development of autoimmune disease or lymphoproliferative diseases (Goronzy and Weyand, 2008; Rudd et al., 2009) . Peripheral cytokines can promote signaling inside CNS (Fil et al., 2011) . In the Framingham study it was observed that higher levels of production of the inflammatory cytokines IL-1 or TNF-αby PBMC was associated with an increased risk for developing AD (Tan et al., 2007) .
It is obvious that peripheral alterations may not reflect exactly what happens inside brain and it is therefore necessary to take this into consideration when analysing our findings. Previous work has already demonstrated that PBMC can be used as a probe to study psychiatric disorders (Cosentino et al., 2009; Gatta et al., 2009; Gladkevich et al., 2004; Magaki et al., 2007; Torres et al., 2009) . It is also important to highlight that cytometric analysis of PBMC is a minimally invasive procedure, easy to replicate or perform in clinical settings.
CTLA-4 is considered one of the most potent negative regulators of T cell activation. CTLA-4 deficient mice develop a severe lymphoproliferative disorder and die within few weeks after birth (Waterhouse et al., 1995) . T cell co-stimulation signalling has progressed from bench to bedside. Inhibition of CD28 pathway is an important strategy to block rejection of transplants or control autoimmune disease (Bour-Jordan et al., 2011; Driessens et al., 2009 ). There are studies using Abatacept (CTLA-4-immunoglobulin) to treat rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis (Linsley and Nadler, 2009) . Although modulation of T cell co-stimulation is already in clinical use and its influence in immune response is well recognized, there are no reports about the role of B7-CD28/CTLA-4 pathway in primary degenerative dementias including Alzheimer disease, frontotemporal dementia and others.
As expected, FTD group was younger than AD. Although AD is the commonest dementia in all ages, it is more prevalent in older people, whilst FTD is just the opposite. In clinical practice, the differential diagnosis in any age is not easy and a biomarker could be very useful. As there are no significant alterations in cytokine expression between these age groups (Faria et al., 2008) , the authors believe that the two groups are comparable and do not interfere with the study conclusion. Immunological parameters change throughout the course of neurodegenerative disease. In order to make the groups more comparable, no clinical dementia rate stage 3 patients were enrolled. The results presented in Table 1 reflected the clinical picture found in both groups since the higher MMSE scores were a good indication of early stage FTD and MMSE was significantly altered in Alzheimer disease.
Conclusion
This work clearly shows that CTLA-4 expression in CD4 + T cells from frontotemporal dementia patients' blood is reduced when compared to Alzheimer and control groups. The difference in HLA-DR and IL-1α expression in CD14 + in FTD patients compared to AD patients supports the idea that the role of immune system in FTD is different from AD and needs further investigation. As far as we know, this is the first study to demonstrate an alteration in B7-CD28/CTLA-4 in primary degenerative dementias, particularly FTD. Although we cannot clarify the importance of molecules associated with co-stimulatory signaling in FTD neurodegenerative processes, these results clearly highlight a new path to be investigated. 
